| Dr Myron M Laban, MD | |
|
3535 W 13 Mile Rd, Ste 437, Royal Oak, MI 48073 | |
| (248) 288-2210 | |
| (248) 280-0505 |
| Full Name | Dr Myron M Laban |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 3535 W 13 Mile Rd, Royal Oak, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104808120 | NPI | - | NPPES |
| 1052880 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 4301024828 (Michigan) | Primary |
| Entity Name | Lmt Rehabilitation Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154372746 PECOS PAC ID: 0446265268 Enrollment ID: O20071113000156 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.
A collaborative research effort by Australian and US scientists has led to the discovery of a promising new approach to treating some of the worst types of leukaemia, including an aggressive leukaemia that mostly affects babies.
Delicate, threadlike protrusions used by cancer cells when they invade other tissues in the body could also help them escape control mechanisms supposed to eliminate them, a research group led by led by Bradley Davidson in the University of Arizona's department of molecular and cellular biology reports in Nature Cell Biology.
By not implementing a neuroblastoma screening program between 1989 and 2002, the United States and Canada saved $574.1 million in health costs, avoided the unnecessary treatment of more than 9,200 children, and avoided false-positive findings in more than 5,000 children, according to a new study in the August 3 issue of the Journal of the National Cancer Institute.
iTech Medical, Inc. (OTCBB: IMSU) (FWB: 0IM), an information technology company, showcased the Company's proprietary information technology platform, Muscle Pattern Recognition (MPR), at BioContact Quebec 2009.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Myron M Laban, MD 3535 W 13 Mile Rd, Ste 437, Royal Oak, MI 48073-6770 Ph: (248) 288-2210 | Dr Myron M Laban, MD 3535 W 13 Mile Rd, Ste 437, Royal Oak, MI 48073 Ph: (248) 288-2210 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.
A collaborative research effort by Australian and US scientists has led to the discovery of a promising new approach to treating some of the worst types of leukaemia, including an aggressive leukaemia that mostly affects babies.
Delicate, threadlike protrusions used by cancer cells when they invade other tissues in the body could also help them escape control mechanisms supposed to eliminate them, a research group led by led by Bradley Davidson in the University of Arizona's department of molecular and cellular biology reports in Nature Cell Biology.
By not implementing a neuroblastoma screening program between 1989 and 2002, the United States and Canada saved $574.1 million in health costs, avoided the unnecessary treatment of more than 9,200 children, and avoided false-positive findings in more than 5,000 children, according to a new study in the August 3 issue of the Journal of the National Cancer Institute.
iTech Medical, Inc. (OTCBB: IMSU) (FWB: 0IM), an information technology company, showcased the Company's proprietary information technology platform, Muscle Pattern Recognition (MPR), at BioContact Quebec 2009.
› Verified 5 days ago
Randi J. Long, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Road, Royal Oak, MI 48073 Phone: 248-809-1227 Fax: 248-809-1228 | |
Dr. Ronald S Taylor, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3535 W 13 Mile Rd, Ste 437, Royal Oak, MI 48073 Phone: 248-288-2210 Fax: 248-280-0505 | |
Dr. Julie Ann Ferris, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3535 W 13 Mile Rd, Suite 437, Royal Oak, MI 48073 Phone: 248-288-2210 Fax: 248-589-9875 | |
Michael W Garmo, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 3601 West Thirteen Mile Road, Royal Oak, MI 48073 Phone: 248-630-6229 | |
Dr. Shawn Adam Achtman, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-5000 | |
Dr. Douglas Joseph Boven Ii, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3535 W 13 Mile Rd Ste 437, Royal Oak, MI 48073 Phone: 248-288-2210 Fax: 248-589-9875 |